Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the effects of MC-1 [pyridoxal phosphate] alone and in combination with an ACE inhibitor on ambulatory blood pressure and metabolic function in hypertensive patients with type 2 diabetes mellitus

Next Previous
Trial Profile

Evaluation of the effects of MC-1 [pyridoxal phosphate] alone and in combination with an ACE inhibitor on ambulatory blood pressure and metabolic function in hypertensive patients with type 2 diabetes mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisinopril (Primary) ; Pyridoxal phosphate (Primary)
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms MATCHED
  • Sponsors Medicure

Most Recent Events

  • 16 Apr 2008 Interim results were reported at ATVB 2008, according to a Medicure media release.
  • 23 Aug 2007 The expected completion date for this trial is now 1 Jul 2005.
  • 30 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top